XQuick Search
Association Between Serum HMGB-1 (High Mobility Group Box-1) Levels and Clinical Course in Patients With COVID-19
Amed Trak1, Enes Seyda Şahiner1, Elif Unal1, Dilara Bulut Gokten1, Esra Fırat Oğuz2, İhsan Ateş11Ankara City Hospital, Department Of Internal Medicine, Ankara, Turkey2Ankara City Hospital, Department Of Clinical Biochemistry, Ankara, Turkey
INTRODUCTION: We aimed to investigate the relationship between serum HMGB-1 levels and the clinical course of COVID-19 disease.
METHODS: A total of 86 patients, 43 patients in each group, were included in the study. According to the Ministry of Health's COVID-19 Diagnostic Guide, patients were divided into 2 groups as mild/moderate pneumonia and severe pneumonia. In addition to routine tests, blood samples were taken for serum HMGB-1 level analysis. At the time of blood draw, all patients were within the first 14 days of symptom onset.
RESULTS: HMGB-1 (High mobility group box protein 1) level of the patients in the mild Covid-19 pneumonia group was 4233.84 pg/ml, and the serum HMGB-1 level of the patients in the moderate-severe pneumonia group was 4804.35 pg/ml. There was no significant difference between the two groups (P=0.146).
DISCUSSION AND CONCLUSION: We did not find a significant difference between the two groups in blood samples taken in the first 14 days from the onset of symptoms in COVID-19 patients.
Manuscript Language: English